Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer

被引：4

作者：

Shin, Wonkyo ^{[1
,2
]}

Noh, Joseph J. ^{[3
]}

Baek, Seung Hun ^{[3
]}

Kim, Byoung-Gie ^{[3
]}

Lim, Myong Cheol ^{[1
]}

Park, Sang-Yoon ^{[1
]}

机构：

[1] Natl Canc Ctr, Ctr Gynaecol Canc, 323 Ilsan Ro,Ilsandong Gu, Goyang 10408, Gyeonggido, South Korea

[2] Chungnam Natl Univ, Dept Obstet & Gynaecol, Sejong Hosp, Sejong, South Korea

[3] Sungkyunkwan Univ, Dept Obstet & Gynaecol, Samsung Med Ctr, Sch Med, Seoul, South Korea

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 09期

关键词：

Epithelial ovarian cancer; niraparib; haematological problems; MAINTENANCE THERAPY; PRIMARY SURGERY; BEVACIZUMAB; CHEMOTHERAPY;

D O I：

10.21873/anticanres.15273

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Niraparib is effective against epithelial ovarian cancer (EOC), but with adverse effects. In this study, we retrospectively investigated niraparib maintenance treatment feasibility in Korean patients newly diagnosed with EOC. Patients and Methods: The medical records of 35 patients were reviewed. Data on the baseline clinical characteristics were collected, and adverse effects were described. Results: Sixteen patients underwent treatment suspension or dose reduction. There was no significant difference in adverse effects (A/E) due to the interval between adjuvant chemotherapy conclusion and niraparib initiation. The two groups had similar International Federation of Gynaecology and Obstetrics (FIGO) stages. The number of patients with a history of bevacizumab use was higher in the dose modification group than in the standard dose group. Conclusion: Niraparib use must be considered in those previously treated with bevacizumab. There is a need for prospective research on lower dose (<200 mg) treatments in patients with risk factors.

引用

页码：4603 / 4607

页数：5

共 17 条

[1] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[2] Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].

Coleman, R. L. ;

Fleming, G. F. ;

Brady, M. F. ;

Swisher, E. M. ;

Steffensen, K. D. ;

Friedlander, M. ;

Okamoto, A. ;

Moore, K. N. ;

Ben-Baruch, N. Efrat ;

Werner, T. L. ;

Cloven, N. G. ;

Oaknin, A. ;

DiSilvestro, P. A. ;

Morgan, M. A. ;

Nam, J. -H. ;

Leath, C. A., III ;

Nicum, S. ;

Hagemann, A. R. ;

Littell, R. D. ;

Cella, D. ;

Baron-Hay, S. ;

Garcia-Donas, J. ;

Mizuno, M. ;

Bell-McGuinn, K. ;

Sullivan, D. M. ;

Bach, B. A. ;

Bhattacharya, S. ;

Ratajczak, C. K. ;

Ansell, P. J. ;

Dinh, M. H. ;

Aghajanian, C. ;

Bookman, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415

[3] Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies [J].

Freites-Martinez, A. ;

Santana, N. ;

Arias-Santiago, S. ;

Viera, A. .

ACTAS DERMO-SIFILIOGRAFICAS, 2021, 112 (01) :90-92

[4] Multimodal Treatment of Primary Advanced Ovarian Cancer [J].

Friedrich, Michael ;

Friedrich, Dominique ;

Kraft, Clayton ;

Rogmans, Christoph .

ANTICANCER RESEARCH, 2021, 41 (07) :3253-3260

[5] Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Gonzalez-Martin, A. ;

Pothuri, B. ;

Vergote, I. ;

DePont Christensen, R. ;

Graybill, W. ;

Mirza, M. R. ;

McCormick, C. ;

Lorusso, D. ;

Hoskins, P. ;

Freyer, G. ;

Baumann, K. ;

Jardon, K. ;

Redondo, A. ;

Moore, R. G. ;

Vulsteke, C. ;

O'Cearbhaill, R. E. ;

Lund, B. ;

Backes, F. ;

Barretina-Ginesta, P. ;

Haggerty, A. F. ;

Rubio-Perez, M. J. ;

Shahin, M. S. ;

Mangili, G. ;

Bradley, W. H. ;

Bruchim, I. ;

Sun, K. ;

Malinowska, I. A. ;

Li, Y. ;

Gupta, D. ;

Monk, B. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2391-2402

[6] The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings [J].

Helleday, Thomas .

MOLECULAR ONCOLOGY, 2011, 5 (04) :387-393

[7] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial [J].

Kehoe, Sean ;

Hook, Jane ;

Nankivell, Matthew ;

Jayson, Gordon C. ;

Kitchener, Henry ;

Lopes, Tito ;

Luesley, David ;

Perren, Timothy ;

Bannoo, Selina ;

Mascarenhas, Monica ;

Dobbs, Stephen ;

Essapen, Sharadah ;

Twigg, Jeremy ;

Herod, Jonathan ;

McCluggage, Glenn ;

Parmar, Mahesh ;

Swart, Ann-Marie .

LANCET, 2015, 386 (9990) :249-257

[8] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Macpherson, Euan ;

Watkins, Claire ;

Carmichael, James ;

Matulonis, Ursula .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1382-1392

[9] Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010 [J].

Lim, Myong Cheol ;

Moon, Eun-Kyeong ;

Shin, Aesun ;

Jung, Kyu-Won ;

Won, Young-Joo ;

Seo, Sang Soo ;

Kang, Sokbom ;

Kim, Jae-Weon ;

Kim, Joo-Young ;

Park, Sang-Yoon .

JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (04) :298-302

[10] Clinical pharmacokinetics of bevacizumab in patients with solid tumors [J].

Lu, Jian-Feng ;

Bruno, Rene ;

Eppler, Steve ;

Novotny, William ;

Lum, Bert ;

Gaudreault, Jacques .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) :779-786

← 1 2 →